Sign In
to Vote &
Create Storyboards.
 
Kadcyla is now available for patients with advanced HER2-positive breast cancer. Kadcyla is the first medicine of its kind in breast cancer, consisting of the HER2-targeted antibody, trastuzumab (contained in the medicine Herceptin), linked with the chemotherapy agent, DM1. In response to the pivotal Phase III EMILIA clinical trial, the European Medicines Agency (EMA) has now granted a license for adult patients with advanced HER2-positive breast cancer who have previously received Herceptin and...
2
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard